Compare Amylx Pharmaceuticals Inc (AMLX) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Williams-Sonoma, Inc. — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Williams-Sonoma, Inc. trades at $221.75 (market cap $26.11B). The key difference: Williams-Sonoma, Inc. is far larger — about 13.2× Amylx Pharmaceuticals Inc's market cap, and Williams-Sonoma, Inc. pays a 1.37% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | WSM | |
|---|---|---|
Market Cap | $1.98B | $26.11B |
Sector | Health | Consumer Cyclical |
52-Week High | $18.70 | $240.06 |
52-Week Low | $7.64 | $163.62 |
Enterprise Value | $1.70B | $26.95B |
Dividend Yield | — | 1.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Williams-Sonoma (WSM) trades at $221.75, up 0.9% with a bullish technical signal. The company demonstrates strong profitability with 46.1% gross margins and 54% ROE, though revenue has declined from $8.7B in 2023 to $7.7B in 2025. Recent quarterly earnings have consistently beaten expectations, and the company maintains a $0.76 quarterly dividend. Analyst consensus is mixed with 29% buy ratings but a $215.50 price target below current levels.
WSM faces headwinds from revenue contraction and competitive pressures in home furnishings, though strong margins and consistent earnings beats provide support. The stock trades at premium valuations (P/E 24.9, P/S 3.4) requiring sustained execution. Near-term direction hinges on Q2 2026 earnings due next, with technical support at $217 and resistance at $223.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
